Eight weeks duration of ledipasvir/sofosbuvir (LDV/SOF) can be considered in genotype 1 hepatitis C virus-infected patients who are treatment-naive, do not have cirrhosis, and have a pretreatment viral load <6,000,000 IU/mL. The effectiveness of this regimen, however, has not been fully confirmed by real-world experience. Using data from real-world cohorts, we aimed to determine the effectiveness of 8 weeks of LDV/SOF treatment, examine variables associated with relapse after treatment with this regimen, and compare the effectiveness of 8 weeks and 12 weeks of LDV/SOF treatment. To evaluate the effectiveness of 8 weeks of therapy and characteristics associated with relapse, we used individual patient data from the IFI (Institut f€ ur Interdisziplin€ are Medizin), Burman's Pharmacy, and Kaiser Permanente Southern California. All patients had fibrosis staging assessed with biopsy, transient elastography, or serum biomarkers. We also performed a systematic review and meta-analysis of six additional real-world cohorts, to compare effectiveness of 8 weeks to 12 weeks duration. In our pooled data analysis, 634 patients were treated for 8 weeks with LDV/SOF, of whom all had outcomes of cure or relapse without loss to follow-up. Per protocol rates of sustained virologic response at 12 weeks were 98.1% (622/634) in the full cohort and 97.9% (571/583) among treatment-eligible patients. Exact logistic regression revealed no specific patient characteristics associated with relapse. Our meta-analysis of six additional real-world cohorts, comprised of 5,637 patients, demonstrated similar risk for relapse between 8 weeks and 12 weeks of LDV/SOF (relative risk 5 0.99, 95% confidence interval 0.98-1.00). Conclusion: An 8-week duration of treatment with LDV/SOF is highly effective in properly selected patients; greater use of this regimen is recommended. (HEPATOLOGY 2017;65:1094-1103 
Eight weeks duration of ledipasvir/sofosbuvir (LDV/SOF) can be considered in genotype 1 hepatitis C virus-infected patients who are treatment-naive, do not have cirrhosis, and have a pretreatment viral load <6,000,000 IU/mL. The effectiveness of this regimen, however, has not been fully confirmed by real-world experience. Using data from real-world cohorts, we aimed to determine the effectiveness of 8 weeks of LDV/SOF treatment, examine variables associated with relapse after treatment with this regimen, and compare the effectiveness of 8 weeks and 12 weeks of LDV/SOF treatment. To evaluate the effectiveness of 8 weeks of therapy and characteristics associated with relapse, we used individual patient data from the IFI (Institut f€ ur Interdisziplin€ are Medizin), Burman's Pharmacy, and Kaiser Permanente Southern California. All patients had fibrosis staging assessed with biopsy, transient elastography, or serum biomarkers. We also performed a systematic review and meta-analysis of six additional real-world cohorts, to compare effectiveness of 8 weeks to 12 weeks duration. In our pooled data analysis, 634 patients were treated for 8 weeks with LDV/SOF, of whom all had outcomes of cure or relapse without loss to follow-up. Per protocol rates of sustained virologic response at 12 weeks were 98.1% (622/634) in the full cohort and 97.9% (571/583) among treatment-eligible patients. Exact logistic regression revealed no specific patient characteristics associated with relapse. Our meta-analysis of six additional real-world cohorts, comprised of 5,637 patients, demonstrated similar risk for relapse between 8 weeks and 12 weeks of LDV/SOF (relative risk 5 0.99, 95% confidence interval 0.98-1.00). Conclusion: An 8-week duration of treatment with LDV/SOF is highly effective in properly selected patients; greater use of this regimen is recommended. (HEPATOLOGY 2017; 65:1094 -1103 I n a post hoc analysis of the ION-3 study, treatment-naive patients without cirrhosis and a pretreatment hepatitis C virus (HCV) RNA level of <6,000,000 (6.78 log 10 ) IU/mL had similar rates of relapse when receiving 8 or 12 weeks of ledipasvir/ sofosbuvir (LDV/SOF) (1.9 versus 1.5%, P 5 0.20). (1) Subsequently, current Food and Drug Administration (FDA) labeling stated that an 8-week regimen of LDV/SOF can be considered in treatment-naive patients without cirrhosis and with a pretreatment HCV RNA level <6,000,000 IU/mL. Although substantial cost savings can occur with a shortened Abbreviations: CI, confidence interval; FDA, Food and Drug Administration; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFI, IFI Institut f€ ur Interdisziplin€ are Medizin; LDV, ledipasvir; PP, per protocol; RR, relative risk; SOF, sofosbuvir; SVR, sustained virologic response; SVR12, SVR at 12 weeks posttherapy. duration of treatment, (2) limitations exist regarding this post hoc analysis including lack of statistical power to support the conclusions and intralaboratory and interassay variability in viral levels, which could affect the use of a strict viral load cutoff. (3, 4) Furthermore, prior studies using real-world data have shown differences in outcomes compared to clinical trial data (5) (6) (7) as treatment compliance is less controlled and coordination of care is not standardized.
Given these concerns, validation of the real-world effectiveness of an 8-week duration of LDV/SOF is warranted. In this study, we examined pooled data from the Institut f€ ur Interdisziplin€ are Medizin (IFI), Burman's Pharmacy/Temple University, and Kaiser Permanente Southern California to determine the sustained virologic response (SVR) at 12 weeks posttreatment (SVR12) rate of 8 weeks of LDV/SOF treatment and to evaluate baseline patient and virologic characteristics associated with relapse after 8 weeks of therapy. Our secondary aim was to perform a systematic review and meta-analysis of additional real-world cohort studies, to compare the effectiveness of 8 and 12 weeks of treatment with LDV/SOF, based on the hypothesis that 8 weeks would be noninferior to 12 weeks.
Patients and Methods

STUDY DESIGN AND PRIMARY OUTCOMES
The IFI, Burman's Pharmacy, and Kaiser Permanente Southern California cohorts, described below, were queried for patients age 18 or older, with HCV genotype 1 infection who were treatment-naive, without cirrhosis, received LDV/SOF for 8 weeks duration, and had adequate follow-up time to determine SVR outcomes. We did not restrict our study population to patients with a baseline viral load <6,000,000 IU/mL in order to assess whether 8 weeks of LDV/SOF therapy was effective in those with a higher baseline viral level.
We excluded patients who were posttransplantation or whose posttransplant status was unknown, who were given ribavirin, and who had missing information regarding age, gender, pretreatment viral load, or genotype subtype. In order to assess for an association between fibrosis stage and relapse, we also excluded all patients who did not have fibrosis staging performed by transient elastography, serum biomarkers (fibro-SURE, Hepascore), or liver biopsy within 3 years of undergoing treatment. Data were collected regarding age, gender, race/ethnicity, genotype subtype, pretreatment viral load, fibrosis stage, and human immunodeficiency virus (HIV) coinfection.
The primary outcome was SVR12, defined as plasma HCV RNA level below quantitation or undetectable at least 12 weeks after treatment completion. For patients who did not achieve SVR12, outcomes were reported as a per protocol (PP) analysis, either as relapse or as virologic breakthrough.
STUDY COHORTS
IFI
The IFI cohort represents subjects prospectively enrolled at a single German center and given LDV/ SOF for 8 or 12 weeks, with or without ribavirin, at the provider's discretion. Data were obtained by manual review of records for patients treated from December 2, 2014, through July 10, 2015. 
Kaiser Permanente Southern California
Kaiser Permanente Southern California is a large integrated health care system delivered to members at 14 medical centers. All interactions with the health care system are captured in an integrated electronic medical record system. Data were collected retrospectively from December 2015 to December 2016 for all patients who had completed 8-week LDV/SOF therapy and had adequate follow-up time to determine SVR12 outcomes.
META-ANALYSIS
We determined the SVR12 rate for the entire study cohort and for those considered treatment-eligible based on FDA recommendations. The full study population consisted only of treatment-naive patients without cirrhosis, but those classified as treatment-eligible also had a pretreatment viral load <6,000,000 IU/mL. SVR12 rates were also assessed for various subgroups within the full population and the treatment-eligible population. Two-sided 95% confidence intervals (CIs) for the SVR12 rates were reported, as determined by the Clopper-Pearson method.
We additionally built a multivariable logistic regression model, to ascertain which variables were associated with relapse after 8 weeks of LDV/SOF, based on PP analysis. All patients in the logistic regression model were treatment-eligible per FDA recommendations. The independent variables incorporated in this model were selected a priori, based on potential to affect SVR12 rates or clinical interest including gender, (8) race, (9) genotype subtype, and fibrosis stage. (10) Conditional variables were generated to adjust for age group as well as for study cohort in order to control for heterogeneity in study design and patient population. We used exact logistic regression as the expected number of cell counts for relapse was less than five under the null in several subgroup analyses. Goodness of fit was checked using the Hosmer-Lemeshow method. Analyses were performed using Stata 14.0 (StataCorp LP, College Station, TX).
SYSTEMATIC REVIEW
We conformed to the Meta-analysis of Observational Studies in Epidemiology guidelines, for which a checklist is shown in Supporting Table S1 . (11) V.S. and K.V.K. searched for titles of articles from May 1, 2014, through June 1, 2016, in EMBASE, Medline, and Cochrane Library, using a combination of the following keywords: "Hepatitis C, Chronic," "Hepatitis C," "HCV," "Hepacivirus," "GS-7977," "PSI-7977," "Sofosbuvir," and "Ledipasvir." V.S. additionally performed a manual search for published abstracts from international conference proceedings.
We included studies if they (1) were observational cohort studies of prospective or retrospective design and (2) provided virologic outcomes for patients with hepatitis C genotype 1 infection treated with LDV/ SOF, stratified by 8 or 12 weeks' duration. We excluded studies if they incorporated patients <18 years of age, did not provide virologic outcomes for patients receiving both 8 and 12 weeks of LDV/SOF, or included patients after solid organ transplantation. We also excluded studies if they were not in English. If two or more studies had potential for patient overlap, we used the cohort with the larger sample size or the cohort where we had access to unpublished patient data. For studies in which we were uncertain if the patients treated for 8 weeks were treatment-eligible per FDA recommendations, we contacted and received confirmation directly from the authors. In cases where authors provided unpublished data, (12, 13) we requested treatment eligibility information regarding cirrhosis status, treatment history, and baseline viral load for patients receiving 8 weeks of LDV/SOF and cirrhosis status and treatment history for those receiving 12 weeks of therapy.
V.S. screened titles and abstracts to remove duplicates. V.S. and K.V.K. independently reviewed the remaining studies and determined the final set of studies to be included. The search results and the flowchart for the systematic review are provided in Supporting  Table S2 and Supporting Fig. S1 .
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DATA EXTRACTION AND QUALITY ASSESSMENT
Data extraction was performed by V.S. and checked by C.Y.J. The following data were extracted from each study regarding (1) publication date, first author's surname, and the country of origin and (2) study design, sample size, baseline patient characteristics, and outcome measures.
The risk of bias was assessed using the Cochrane Risk of Bias Assessment Tool: for Non-Randomized Studies of Interventions (14) (Supporting Table S3 ). We included the following domains of bias: confounding, selection of participants, measurement of exposure at baseline, changing exposure during follow-up, missing data (including loss to follow-up), outcome measurement, and selective reporting. We judged each domain of bias as "low," "moderate," "serious," or "critical" risk. We determined the overall quality of evidence supporting the effect of 8 weeks and 12 weeks of therapy using the Ottawa-Newcastle Scale (15) (Supporting Tables S3 and S4 ) Cohort studies with an Ottawa-Newcastle Scale score of 8 or higher were considered high quality. (16) V.S. and C.Y.J. performed the risk of bias analysis, while V.S. and K.V.K. performed the overall quality of evidence assessment separately and then discussed the results for consensus.
STATISTICAL ANALYSIS
We used Stata version 14.0 to perform a random effects meta-analysis for comparison of relapse rate, following the methods developed by DerSimonian and Laird, (17) and a two-sided P > 0.05 for statistical significance. Random effects analysis was chosen to correct for between-study heterogeneity. An additional subgroup analysis was performed to determine if the effect size between 8 and 12 weeks of LDV/SOF differed when analyzing cohorts that excluded patients with cirrhosis. (12, 13) Prior to performing the metaanalysis, we performed a sample size calculation to determine if enough patients were included to evaluate if the effectiveness of 8 weeks was noninferior to 12 weeks of therapy. Assuming an SVR12 rate of 95% for 8 and 12 weeks of treatment, (1) a one-sided alpha of 0.025, power of 90%, and delta of 3%, our calculation estimated that 1,110 patients were required in each group.
We examined statistical heterogeneity by performing I 2 testing. In accordance with the Cochrane Handbook, (18) we interpreted the I 2 values as follows: "0-40%, heterogeneity might not be important; 30-60% may represent moderate heterogeneity; 50-90% may represent substantial heterogeneity; 75-100% may represent considerable heterogeneity." Our proposed method to investigate heterogeneity was to perform a metaregression of the log of the relative risk (RR), weighting the studies by inverse variance, by the following plausible causes of heterogeneity which were preselected a priori: study design (retrospective versus prospective) and inclusion of patients with cirrhosis. Study characteristics were considered to be a significant contributor to heterogeneity if the P value for the coefficient in the multivariable meta-regression was under 0.05. We used Egger's regression test to assess for publication bias. (19) 
Results
From the IFI cohort, data were extracted for 128 patients, of whom 2 were excluded due to being treatment-experienced and 2 were excluded due to loss to follow-up. From Burman's Pharmacy, data were collected on 380 patients, of whom 5 were excluded due to missing information regarding pretreatment HCV viral RNA level and 68 were excluded due to lack of fibrosis staging. Of 775 patients from Kaiser Permanente Southern California treated for 8 weeks, a total of 203 were incorporated into our study, after elimination of patients without fibrosis staging and those who did not have a liver biopsy or transient elastography within 3 years of treatment. After pooling together all cohorts, the final study population consisted of 634 patients given treatment with LDV/SOF without RBV for 8 weeks (IFI 5 124, Burman's Pharmacy 5 307, Kaiser Permanente Southern California 5 203) who had outcomes data available for PP analysis.
BASELINE CHARACTERISTICS
Baseline characteristics of the full study population are summarized in Table 1 . Regarding demographics, the mean age was 56.1 years and patients were primarily Caucasians (60.1%) but with identical proportion of males and females. The majority of patients had a pretreatment HCV viral load <6,000,000 IU/mL (91.9%), though the maximum pretreatment viral RNA level was 59,000,000 IU/mL. More patients were genotype 1a (64.4%) compared to genotype 1b (31.9%). With regard to fibrosis stage, patients were mainly fibrosis stage 0-2 (81.4%), with 18.6% of patients having stage 3 fibrosis. A small percentage of patients had HIV coinfection (2.5%). Table 2 depicts SVR12 rates with 95% CIs for patients receiving 8 weeks of LDV/SOF, as determined by PP analysis, for the entire study cohort (n 5 634) and for patients considered treatment-eligible for 8 weeks duration (n 5 583). The overall SVR12 rate was 98.1% (622/634) for the full cohort and 97.9% (571/583) among those who were treatment-eligible. We additionally determined SVR12 rates by several subgroups including age >65 years, gender, race/ethnicity, geno-subtype, fibrosis stage, baseline viral load, and HIV coinfection. Our analysis demonstrated a 97% SVR12 rate with 8-week treatment in most subgroups, including age >65 years, male gender, genotype 1a infection, and patients with stage 0-2 fibrosis. Furthermore, our analysis revealed 100% SVR12 rates among patients given 8 weeks of treatment with baseline HCV RNA viral level >6,000,000 IU/mL and with HIV coinfection. The SVR12 rate among African Americans was >95% in the full study cohort (95.9%) and the treatment-eligible group (95.8%). For patients with stage 3 fibrosis, the SVR12 rate was 94.1% in the entire population and 93.9% among patients who were eligible for 8 weeks of LDV/SOF.
STUDY OUTCOMES
CHARACTERISTICS OF RELAPSERS AFTER 8-WEEK TREATMENT
In Table 3 , we provide details regarding the 12 patients receiving 8 weeks of LDV/SOF who had demonstration of virologic relapse. Relapsers were Table 4 displays our multivariable model examining the association between selected independent variables and relapse in those receiving 8 weeks of LDV/SOF. Our results demonstrated that none of the independent variables in the model were significantly associated with relapse, though there was a trend toward significance among patients with stage 3 fibrosis (P 5 0.059, 95% CI 0.94-23.1).
PREDICTORS OF SVR12 AMONG PATIENTS RECEIVING 8-WEEK TREATMENT
META-ANALYSIS
Of 707 records initially identified, 10 records were found to meet the inclusion and exclusion criteria (Supporting Fig. S1 ). Subsequently, four studies were removed due to potential for overlap (Supporting Table S5 ). This led to selection of six studies for inclusion, of which one was a published manuscript and the remainder were published abstracts. (12, 13, (20) (21) (22) (23) A total of 5,637 cases were identified, with the study sample size varying from 90 to 1,981 patients. Details regarding the selected studies are outlined in Table 5 . For two of the included studies, (12, 13) we obtained unpublished data regarding baseline patient characteristics and SVR12 outcomes.
Based on a pooled PP analysis of the six studies, overall SVR12 rates were 95.8% (2,196/2,293) among patients receiving 8 weeks of treatment and 97.2% (3,251/3,344) for patients given 12 weeks of LDV/ SOF. When the studies were combined using a random effects model, the RR for relapse for 8 weeks versus 12 weeks was estimated to be 0.99 (95% CI 0.98-1.00), indicating similar effectiveness between 8 and 12 weeks of treatment with LDV/SOF (Fig. 1) . The I 2 for heterogeneity was 0%, indicating no heterogeneity. Egger's regression testing did not reveal Gill et al. (22) Lai et al. (23) Crespo et al. (21) publication bias (Supporting Table S6 ). Subgroup analysis revealed similar RRs for relapse when evaluating studies incorporating patients with cirrhosis (RR 5 0.99, 95% CI 0.98-1.00) and without cirrhosis (RR 5 0.99, 95% CI 0.96-1.01).
Discussion
Our analysis of individual patient data from four realworld cohorts and meta-analysis of six additional cohorts contains several important findings. First, we demonstrate an overall SVR12 rate of 97.9% among appropriately selected patients treated for 8 weeks, based on PP analysis, thereby supporting the high SVR rates found in the ION-3 study. Furthermore, we show effectiveness approaching 94% or greater among several different subgroups including the elderly, those of African American race, those with genotype 1a, those with HIV coinfection, those with pretreatment HCV viral RNA level >6,000,000 IU/mL, and those with fibrosis stage 0-3. Finally, our meta-analysis suggests similar efficacy between 8 weeks and 12 weeks of treatment with LDV/ SOF in appropriately selected patients. Our study has several strengths including evaluation of the largest cohort of patients given 8 weeks of treatment with availability of fibrosis staging in all patients, inclusion of a diverse patient population across two continents, and complete posttreatment outcome data without loss to follow-up. The meta-analysis component of our study represents the largest sample to date of real-world patients comparing the effectiveness of 8 weeks with 12 weeks of LDV/SOF.
Recently published studies have demonstrated that 8 weeks of LDV/SOF treatment is used in only 44%-55% of patients eligible to receive this regimen, (13, 24, 25) likely due to the perception that longer length of treatment yields higher cure rates. Our meta-analysis comparing 8 weeks of LDV/SOF among patients eligible for this regimen to 12 weeks of LDV/SOF demonstrated statistically similar risk of relapse. The efficacy between the two study groups remained similar even after subgroup analysis of studies excluding patients with cirrhosis who received 12 weeks of therapy. Given our findings, we encourage providers to consider using 8 weeks of LDV/SOF, thereby potentially reducing health care costs and increasing access to care.
Currently, guidelines from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America do not recommend shortened treatment duration in African Americans and those with HIV coinfection, potentially leading to greater preference among providers for 12 weeks' duration in these populations. (26) However, our analysis demonstrated SVR12 rates of >95% in these subgroups. Specifically regarding patients with HIV coinfection, our analysis in fact demonstrated SVR12 rates of 100%. Although our sample size of HIV-coinfected patients was too small to draw conclusions, our findings support the similarly high SVR12 rates demonstrated by Ingiliz et al. (27/28, 96 .5%). (27) We suggest further validation of 8 weeks of LDV/SOF treatment in treatment-naive, HIV-coinfected patients without cirrhosis as these patients may achieve high SVR12 rates with shortened duration of treatment.
With regard to African Americans, an analysis by Wilder et al. of African American patients enrolled in the ION studies showed that the overall SVR12 rate among 81 patients receiving 8 weeks of LDV/SOF approached 91%. (9) However, when categorized by pretreatment viral load <6,000,000 IU/mL, SVR12 rates were similar between African Americans (26/27, 96%) and Caucasians (93/96, 97%). Our study of a larger sample of 167 African Americans who were 8-week treatment-eligible demonstrated an SVR12 rate of 95.8%, which was statistically similar to cure rates seen among Caucasians and Hispanics in our study population. Our findings are corroborated by the results from Backus et al., who also demonstrated that African American race was not associated with reduced likelihood of SVR12 when limited to patients without cirrhosis and with a baseline viral load <6,000,000 IU/mL. (12) Backus et al., (13) Buggisch et al., (20) Crespo et al., (21) Gill et al., (22) and Lai et al. (23) When selecting a patient to receive a shortened course of LDV/SOF, it is imperative for the clinician to assess if the patient may have a lower likelihood of SVR. Therefore, we investigated baseline patient and virologic characteristics that were associated with relapse. Our analysis did not reveal any specific patient or virologic characteristics to be associated with relapse, though a trend toward relapse was seen among patients with stage 3 fibrosis. Considering the lack of statistical significance and small number of relapsers, however, we do not believe that stage 3 fibrosis is a contraindication to an 8-week course of LDV/SOF in all patients. However, it is notable that among the 7 relapsers with stage 3 fibrosis, 5 were African American. Given these findings, 12 weeks of LDV/SOF may be preferred to 8 weeks in African American patients with stage 3 fibrosis.
There are important implications regarding the findings from our study. First, use of 8 weeks of treatment in those who qualify could lead to substantial cost savings to the health care system. (28) The wholesale acquisition cost for LDV/SOF in the United States is $1,125 per pill. Therefore, an 8-week course of therapy would cost $63,000 compared to $94,500 for a 12-week course, yielding a net savings of $31,500 per patient; such savings may potentially lead to 30% more patients being treated. (28) The potential cost savings are of particular importance as we are in an era of substantially high cure rates for HCV and should emphasize cost reduction so that all patients can be treated, particularly in regions of the world where health care resources are limited and access to care may be restricted. Second, our findings demonstrated an SVR12 rate of 100% among treatment-naive patients without cirrhosis treated for 8 weeks with a baseline viral load >6,000,000 IU/mL. As suggested by O'Brien et al., the use of a strict viral load cutoff to determine eligibility for 8 weeks of treatment may not be fully valid due to lack of statistical power. (4) Our findings indicate the need for additional studies to determine whether the HCV RNA level cutoff established by ION-3 can be increased to encompass more patients.
The results of our study must be interpreted in the context of its limitations. In the individual patient data analysis, our primary limitation relates to the retrospective data collection for certain cohorts and the biases associated with this study design. However, we believe these biases are minimized because baseline patient and virologic characteristics, as well as the primary outcome, are objective and easily identifiable. In addition, as outcomes reported were primarily PP SVR12 rates, we may have overestimated the SVR12 rates in our primary analysis of patients receiving 8-week LDV/SOF. Given that findings from other real-world cohorts also demonstrate similarly high SVR12 rates, (13, 24, 25, 27, 29) we believe this is unlikely. Additionally, we were unable to account for the role of interleukin28bgenotype and baseline resistance-associated variants in leading to relapse after 8 weeks of treatment. We were able to analyze variables that may be most pertinent to clinicians such as gender, race/ethnicity, fibrosis stage, and genotype subtype.
The meta-analysis is further limited in that the majority of studies used were abstracts that have not undergone the same degree of peer review as published articles. Unfortunately, this limitation cannot be fully overcome because LDV/SOF has only been commercially available since October 2014, and therefore, reporting of real-world data at this time is limited primarily to abstracts presented at international conference proceedings. We attempted to mitigate this limitation through contact with study authors to verify the findings reported in Table 5 .
In conclusion, 8 weeks of treatment with LDV/ SOF based on our examination of four real-world cohorts has overall effectiveness of 97.9% in appropriately selected patients. Furthermore, SVR12 rates approached 94% or greater among all subgroups, and no specific baseline characteristic was associated with greater risk of relapse. Finally, 8 weeks of LDV/SOF among eligible patients was noninferior to 12 weeks of therapy. We propose incorporation of the 8-week treatment course into current treatment guidelines to increase use of this regimen, thereby leading to cost savings and increased patient access to treatment.
